Ideally, a basket trial specifically for patients with low- and/or intermediate-positive breast cancer could provide answers on this question, testing neo-adjuvant ICB-combinations such as anti-PD1 plus endocrine treatment or ICB with other immuno-oncology agents such as anti-CTLA4 plus anti-PD154. The gene discussed is CTLA4; the disease is breast carcinoma.